The coronavirus illness 2019 (COVID-19) has spread to over 200 countries and infected over 70 million individuals since December 2019. The precise nature of the SARS-CoV-2 infection is yet unknown. In this study, we look at whether a C-reactive protein biomarker can predict clinical outcome or is linked to the severity of COVID-19 illness. Potential research published from the COVID-19 pandemic to May 2022 was found using the databases MEDLINE, Hinari, Google Scholar, and Google search. To extract relevant facts from each original report, a format established in a Microsoft Excel spreadsheet was employed. The retrieved data were transferred to STATA/MP version 16.0 software for further analysis. Keywords such as "COVID-19," "SARS-CoV-2," and "C-reactive protein," among others, were searched to find relevant papers. Only studies that reported mean C-reactive protein levels and COVID-19 disease stage results were included. The review contained twenty papers. All investigations indicated that individuals with severe COVID-19 had considerably greater levels of C-reactive protein than patients with moderate illness. This review indicated that a specific biomarker may still be used to predict the risk of disease progression in asymptomatic and/or slightly too seriously unwell persons.
At the end of February 2020, the lifestyles of individuals all over the globe were drastically altered by the emergence of a new illness known as COVID-19. This study aims to analyze covid-19 pandemic and its impact on psychological distress, malignancy and chronic diseases. The research method used in this study is a qualitative descriptive method. The type of data used in this study is qualitative data, which is categorized into two types, namely primary data and secondary data. Sources of data obtained through library research techniques (library study) which refers to sources available both online and offline such as: scientific journals, books and news sourced from trusted sources. The results of this study indicate that Covid-19 has a negative impact on the QOL of patients suffering from cancer, distress, and chronic illness. Furthermore, it exacerbates anaemia and fatigue in cancer patients, as well as hypertension or diabetes in cardiovascular patients.
(COVID-19) Finding a cure for Corona virus sickness in 2019 will be a difficult task for researchers all over the globe, since it is associated with significant lung damage and the potential for multiple organ failure. To far, dexamethasone has shown substantial benefits in COVID-19, reducing mortality while improving recovery. There is a reduction in inflammation due to a reduction in inflammation-related immune responses and a decrease in cytokine production, which prevents COVID-19 from becoming more severe. Dexamethasone's significance in the treatment of COVID-19 is currently unproven. When it comes to combating this pandemic, COVID-19's pathophysiology and dexamethasone's efficacy are the deciding factors.
Cancer-related anemia (CRA) is a complicated and multifaceted problem that can occur as a result of tumor, as an adverse reaction of chemotherapeutic agent, or as a result of neurotoxic effects. The symptoms of CRA vary depending on an individual's response to blood loss or reduction in the number of red blood cell production. Patients with severe anemia have different characteristics depending on the type of haematological malignancy they have. Clinical and biochemical evaluations, as well as bone marrow examinations, may be useful diagnostic tools in many cases. Iron therapy can be usedalone or in combination with ESA to improve the response of Hb and to decrease the need of RBC transfusion. lood transfusion carries a number of risks, some of which can be mitigated or even eliminated.. Even though erythropoietin-stimulating agents (ESAs) have been shown to be effective in preventing anemia and reducing the need for blood transfusions, it would be helpful for identifying high-risk patient groups that would benefit the most from these expensive treatments. Blood transfusions should be used on a specific instance basic principle in patients with advanced cancer, depending on the extent of distressing symptoms and life expectancy.
Viral hepatitis constitutes a global health problem; previous studies have affirmed a considerable morbidity and mortality from both acute infections and chronic complications. On the other hand, Human Immunodeficiency Virus (HIV) infection is also of known burden. Determining prevalence measures of these viruses is crucial for establishing appropriate country specific strategies regarding prevention, diagnosis, and containment. The data for this research were records from 2-year period from 20-2018, a total of 1.968 cases were collected from two years. In 2017, a total of 696, (429) Libyan and (267) expatriate, only one infected Libyan and expatriate equally with HCV in June. A total of 1272 cases in 2018, 543 were no Libyan cases with viral infection and 729 Expatriates recorded infection with 8 cases (3 HBSAg and 5 HCV) in November, 7 (one cases with HIV, two cases with HBSAg and 4 cases with HCV). According to the seasons, HIV was recorded with one case (10) in the autumn while the highest HBSAg infected was observed in autumn 5 (50%) followed by summer 4 (40%) and the highest HCV infected was recorded in autumn 9 (90%) followed by summer 3 (30%) and winter 1 (10%).
The two most prevalent causes of end-stage renal disease nowadays are thought to be diabetic mellitus (DM) and hypertension (ESRD). In addition to discussing the function of DM in ESRD, this study reviews glucose metabolism and the treatment of hyperglycemia in these patients. Although strict glycemic control and ESRD patient survival were not significantly correlated in numerous big trials, it is advised that glycemic control be prioritised as the primary therapeutic objective in the care of these patients to minimise harm to other organs. When fasting blood sugar is less than 140 mg/dL, 1-hour postprandial blood sugar is less than 200 mg/dL, and glycosylated haemoglobin (HbA1c) is 6-7 in type 1 diabetes patients and 7-8 in type 2 diabetes patients, glycemic control is ideal. Given its potentially deadly side effect, lactic acidosis, metformin administration should be avoided in patients with chronic renal failure (CRF), while glipizide and repaglinide seem to be preferable options.
Background: Antibiotic resistance is a growing global public health concern because it jeopardizes the effective control and treatment of bacterial infections. The purpose of this study was to determine the bacterial profiles and susceptibility patterns to Imipenem, Augmentin, and Ceftriaxone in various clinical specimens from Al Saleem laboratory in Benghazi, Libya. Methods: Two separate studies were carried out. Each experiment lasted three months. The patients' clinical samples included wound swabs, urine, sperm, blood, high vaginal swabs, and cerebrospinal fluid. Bacterial species were isolated and identified using standard microbiological methods in each study. Kirby-Bauer disc diffusion was used to conduct antimicrobial susceptibility tests from September 2020 to November 2020. Results: There were 711 isolates obtained from 535 female and 503 male patients. The most common organisms isolated from specimens were E. coli spp, Klebsiella spp, and Staph aureus. Conclusion: Bacterial resistance levels to various antibiotics varied greatly. We found that Augmentin has less activity against gram negative bacteria isolated from clinical specimens, whereas Imipenem has a much stronger effect on isolates than Augmentin. Appropriate monitoring of prevalent pathogenic organisms and their sensitivities will assist clinicians in making appropriate antibiotic treatment choices to avoid the spread of antimicrobial resistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.